What is the share price of Sai Life Sciences Ltd (SAILIFE) today?
The share price of SAILIFE as on 19th March 2025 is ₹706.95. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Sai Life Sciences Ltd (SAILIFE) share?
The past returns of Sai Life Sciences Ltd (SAILIFE) share are- Past 1 week: -0.91%
- Past 1 month: 5.21%
- Past 3 months: -4.00%
- Past 6 months: -7.55%
- Past 1 year: -7.55%
- Past 3 years: N/A%
- Past 5 years: -7.55%
What are the peers or stocks similar to Sai Life Sciences Ltd (SAILIFE)?
The peers or stocks similar to Sai Life Sciences Ltd (SAILIFE) include:What is the market cap of Sai Life Sciences Ltd (SAILIFE) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sai Life Sciences Ltd (SAILIFE) is ₹14711.59 Cr as of 19th March 2025.What is the 52 week high and low of Sai Life Sciences Ltd (SAILIFE) share?
The 52-week high of Sai Life Sciences Ltd (SAILIFE) is ₹808.80 and the 52-week low is ₹639.15.What is the PE and PB ratio of Sai Life Sciences Ltd (SAILIFE) stock?
The P/E (price-to-earnings) ratio of Sai Life Sciences Ltd (SAILIFE) is 177.68. The P/B (price-to-book) ratio is 15.09.Which sector does Sai Life Sciences Ltd (SAILIFE) belong to?
Sai Life Sciences Ltd (SAILIFE) belongs to the Health Care sector & Biotechnology sub-sector.How to buy Sai Life Sciences Ltd (SAILIFE) shares?
You can directly buy Sai Life Sciences Ltd (SAILIFE) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Sai Life Sciences Ltd
SAILIFE Share Price
706.951.20% (+8.35)
SAILIFE Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
SAILIFE Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 106.61 | 15.09 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 48.65 | 6.21 | 0.55% |
SAILIFE Analyst Ratings & Forecast
Detailed Forecast 67%
Analysts have suggested that investors can buy this stock
from 3 analysts
Price Upside
Earnings Growth
Rev. Growth
SAILIFE Company Profile
Sai Life Sciences Limited is a contract research, development, and manufacturing organization (CRO/CDMO) providing tailored services for pharmaceutical and biotechnology industries, from drug discovery to commercial launch.
Investor Presentation
View olderSAILIFE Similar Stocks (Peers)
Compare with peersBIOCON
PE Ratio
40.06
1Y Return
39.13%
Buy Reco %
73.33
ONESOURCE
PE Ratio
-46.73
1Y Return
6.60%
Buy Reco %
—
PANACEABIO
PE Ratio
-2,260.52
1Y Return
218.08%
Buy Reco %
—
3BBLACKBIO
PE Ratio
47.39
1Y Return
135.71%
Buy Reco %
—
HESTERBIO
PE Ratio
63.23
1Y Return
1.02%
Buy Reco %
—
SAILIFE Forecasts
Price
Revenue
Earnings
SAILIFE Share Price Forecast
2024
Current
₹706.95
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2024
Current
₹706.95
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
SAILIFE Company Revenue Forecast
2024
Current
₹1.49
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2024
Current
₹1.49
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
SAILIFE Stock EPS (Earnings Per Share) Forecast
2024
Current
₹46.93
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹
2024
Current
₹46.93
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹
SAILIFE
Income
Balance Sheet
Cash Flow
Annual Normal View
SAILIFE Income Statement
Annual Normal View
| Financial Year | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 700.74 | 743.35 | 787.18 | 897.74 | 1,245.11 | 1,494.27 | 1,584.80 | |||||||
Raw Materials | 188.22 | 207.72 | 235.24 | 262.22 | 427.18 | 423.30 | 1,181.53 | |||||||
| Power & Fuel Cost | 25.36 | 27.04 | 27.25 | 31.86 | 43.73 | 49.49 | ||||||||
| Employee Cost | 205.57 | 213.82 | 231.61 | 300.82 | 417.29 | 494.91 | ||||||||
| Selling & Administrative Expenses | 45.25 | 58.20 | 58.98 | 58.81 | 60.82 | 81.28 | ||||||||
| Operating & Other expenses | 55.18 | 51.09 | 39.47 | 89.70 | 99.23 | 129.06 | ||||||||
EBITDA | 181.16 | 185.48 | 194.63 | 154.33 | 196.86 | 316.23 | 403.27 | |||||||
| Depreciation/Amortization | 44.26 | 54.70 | 79.57 | 90.16 | 99.43 | 119.44 | 132.13 | |||||||
| PBIT | 136.90 | 130.78 | 115.06 | 64.17 | 97.43 | 196.79 | 271.14 | |||||||
| Interest & Other Items | 23.81 | 21.70 | 33.14 | 54.48 | 81.02 | 87.56 | 86.17 | |||||||
| PBT | 113.09 | 109.08 | 81.92 | 9.69 | 16.41 | 109.23 | 184.97 | |||||||
| Taxes & Other Items | 39.60 | 32.76 | 20.82 | 3.47 | 6.42 | 26.43 | 46.98 | |||||||
| Net Income | 73.49 | 76.32 | 61.10 | 6.22 | 9.99 | 82.80 | 137.99 | |||||||
| EPS | 44.90 | 46.61 | 36.14 | 3.56 | 5.68 | 46.93 | 78.12 | |||||||
| DPS | 0.00 | 0.00 | 0.00 | 39.63 | 38.33 | 0.00 | 0.00 | |||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 11.15 | 6.75 | 0.00 | 0.00 |
SAILIFE Company Updates
FY 2025
Investor Presentation
Feb 25PDF
Feb 7PDF
SAILIFE Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareBiotechnology
Compare valuation on Screener
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Sai Life Sciences Ltd | 177.68 | 15.09 | — |
| Biocon Ltd | 40.06 | 1.62 | 0.15% |
| Onesource Specialty Pharma Ltd | -46.73 | 46.19 | — |
| Panacea Biotec Ltd | -2,260.52 | 3.13 | — |
SAILIFE Stock Price Comparison
Compare SAILIFE with any stock or ETFCompare SAILIFE with any stock or ETF
SAILIFE
SAILIFE Shareholdings
SAILIFE Promoter Holdings Trend
Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 4.40%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
SAILIFE Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 8.21%
Increased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has increased by 4.08%
SAILIFE Shareholding Pattern
SAILIFE Shareholding History
Foreign Institutions
Mutual Funds Invested in SAILIFE
A list of mutual funds holding the stock, ranked on the basis of Market-cap held which is calculated as the value of stock held in the portfolio divided by its market cap
Increased Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has increased by 5.95%
Top 5 Mutual Funds holding Sai Life Sciences Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.2012% | Percentage of the fund’s portfolio invested in the stock 0.34% | Change in the portfolio weight of the stock over the last 3 months 0.34% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 197/244 (+39) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0065% | Percentage of the fund’s portfolio invested in the stock 2.47% | Change in the portfolio weight of the stock over the last 3 months 2.47% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 19/50 (+30) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9495% | Percentage of the fund’s portfolio invested in the stock 2.63% | Change in the portfolio weight of the stock over the last 3 months 2.63% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 15/61 (+45) |
Compare 3-month MF holding change on Screener
smallcases containing SAILIFE stock
Looks like this stock is not in any smallcase yet.
SAILIFE Events
SAILIFE Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SAILIFE Dividends
Hmm, looks like data is unavailable here. Please come back after some timeSAILIFE Stock News & Opinions
Articles & Videos
Earnings
Sai Life Sciences consolidated net profit rises 35.95% in the December 2024 quarter
Net profit of Sai Life Sciences rose 35.95% to Rs 53.85 crore in the quarter ended December 2024 as against Rs 39.61 crore during the previous quarter ended December 2023. Sales rose 14.64% to Rs 439.78 crore in the quarter ended December 2024 as against Rs 383.63 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales439.78383.63 15 OPM %27.2325.11 - PBDT105.7484.35 25 PBT71.6552.94 35 NP53.8539.61 36 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Sai Life Sciences schedules board meeting
Sai Life Sciences will hold a meeting of the Board of Directors of the Company on 6 February 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Sai Life Sciences spurts on debut
The scrip was listed at Rs 660, exhibiting a premium of 20.22% to the issue price. So far, the stock has hit a high of 675 and a low of 651.20. On the BSE, over 7.98 lakh shares of the company were traded in the counter so far. The initial public offer (IPO) of Sai Life Sciences was subscribed 10.26 times. The issue opened for bidding on Wednesday (11 December 2024) and it closed on Friday (13 December 2024). The price band of the IPO is fixed at Rs 522'549 per share. The IPO comprised a fresh issue of equity shares worth up to Rs 950 crore and an offer for sale of 3,81,16,934 equity shares aggregating up to Rs 2,092.62 crore by existing shareholders. The promoters and promoter group hold an aggregate of 41.82% of the pre-offer issued and paid-up equity share capital. Their post-IPO shareholding is expected to be around 35.24%. Out of the proceeds from the fresh issue, Rs 720 crore will be used for the repayment/prepayment of all or certain outstanding borrowings, with the remaining amount allocated for general corporate purposes. Ahead of the IPO, Sai Life Sciences on Tuesday, 10 December 2024 raised Rs 912.78 crore from anchor investors. The board allotted 1.66 crore shares at Rs 549 each to 63 anchor investors. Sai Life Sciences is an innovator-focused contract research, development, and manufacturing organization (CRDMO). It provides end-to-end services across the drug discovery, development, and manufacturing value chain for small-molecule new chemical entities (NCE) to global pharmaceutical innovator companies and biotechnology firms. The company reported a consolidated net profit of Rs 28.01 crore and net sales of Rs 675.29 crore for the six months ended on 30 September 2024.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Shares of Sai Life Sciences lists today
The equity shares of Sai Life Sciences (Scrip Code: 544306) are listed effective 18 December 2024 and admitted to dealings on the Exchange in the list of ''B'' Group Securities. Powered by Capital Market - Live
3 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 16.35%, vs industry avg of 19.04%
Over the last 5 years, market share decreased from 9.17% to 8.1%
Over the last 5 years, net income has grown at a yearly rate of 2.41%, vs industry avg of 2.04%